{
    "ticker": "KTTAW",
    "name": "Kintara Therapeutics, Inc.",
    "description": "Kintara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cancer. Founded in 2018, Kintara aims to address significant unmet medical needs in oncology through its proprietary drug candidates and strategic partnerships. The company's lead product, VAL-083, is an investigational therapy that has shown promise in treating various cancers, including glioblastoma multiforme (GBM), a highly aggressive brain cancer. Kintara is committed to advancing its clinical trials to evaluate the efficacy and safety of VAL-083, and it is also exploring other potential applications for the drug. In addition to VAL-083, Kintara is developing other therapeutic candidates that leverage cutting-edge research in cancer biology and drug delivery systems. With a focus on patient-centric solutions and collaboration with leading research institutions, Kintara Therapeutics is positioning itself as a significant player in the fight against cancer and striving to bring hope to patients through groundbreaking treatments.",
    "industry": [
        "Biopharmaceutical",
        "Healthcare"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2018",
    "website": "https://www.kintara.com",
    "ceo": "Saiid Zarrabian",
    "social_media": {
        "twitter": "https://twitter.com/KintaraTx",
        "linkedin": "https://www.linkedin.com/company/kintara-therapeutics/"
    },
    "investor_relations": "https://investors.kintara.com",
    "key_executives": [
        {
            "name": "Saiid Zarrabian",
            "position": "CEO"
        },
        {
            "name": "Rita G. B. G. A. K. Reilly",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "VAL-083"
            ]
        }
    ],
    "seo": {
        "meta_title": "Kintara Therapeutics, Inc. | Innovative Cancer Treatments",
        "meta_description": "Kintara Therapeutics, Inc. is focused on developing innovative therapies for cancer treatment. Learn more about our lead product VAL-083 and our commitment to oncology.",
        "keywords": [
            "Kintara Therapeutics",
            "VAL-083",
            "Cancer Treatment",
            "Biopharmaceutical",
            "Glioblastoma",
            "Oncology"
        ]
    },
    "faq": [
        {
            "question": "What is Kintara Therapeutics known for?",
            "answer": "Kintara Therapeutics is known for developing innovative therapies for the treatment of cancer, particularly its lead product VAL-083."
        },
        {
            "question": "Who is the CEO of Kintara Therapeutics?",
            "answer": "Saiid Zarrabian is the CEO of Kintara Therapeutics, Inc."
        },
        {
            "question": "Where is Kintara Therapeutics headquartered?",
            "answer": "Kintara Therapeutics is headquartered in San Diego, California, USA."
        },
        {
            "question": "What is VAL-083?",
            "answer": "VAL-083 is Kintara's lead investigational therapy aimed at treating various forms of cancer, including glioblastoma multiforme."
        },
        {
            "question": "When was Kintara Therapeutics founded?",
            "answer": "Kintara Therapeutics was founded in 2018."
        }
    ],
    "competitors": [
        "CLDX",
        "KURA",
        "RGLS",
        "IMRA"
    ],
    "related_stocks": [
        "AMGN",
        "BMY",
        "GILD",
        "MRNA"
    ]
}